This study aims to validate a difference in blood microbial signature between Alzheimer's patients and control subjects in order to propose potential innovative strategies
This is a pilot study only carried out in Montpellier, aimed at comparing AD patients with control subjects, including men / women aged between 50 and 85 years. The diagnosis of AD patients is based on international criteria. Metagenomics and proteomics will be used to determine the composition of the microbiota in whole blood and stools, but also the metabolomic profile in plasma, stool and the urines.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
120
One time blood, stool and urine samples will be taken.
Facultative polysomnography
Montpellier university hospital
Montpellier, France
RECRUITINGConcentration of bacterial 16S rDNA in stools
Concentration of bacterial 16S rDNA in stools
Time frame: 22 months
Concentration of bacterial 16s DNA in blood
Concentration of bacterial 16s DNA in blood
Time frame: 22 months
Multiomics microbiota signature in AD
Multiomics microbiota signature in AD
Time frame: 22 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.